Announcement • Jun 04
Kaisa Health Group Holdings Limited, Annual General Meeting, Jun 29, 2026 Kaisa Health Group Holdings Limited, Annual General Meeting, Jun 29, 2026, at 11:00 China Standard Time. Location: conference room luxe lab, 20/f., office plus @sheung wan, nos. 93-103 wing lok street, sheung wan, Hong Kong Reported Earnings • Mar 26
Full year 2025 earnings released: HK$0.009 loss per share (vs HK$0.009 loss in FY 2024) Full year 2025 results: HK$0.009 loss per share (in line with FY 2024). Revenue: HK$139.1m (down 25% from FY 2024). Net loss: HK$46.7m (flat on FY 2024). Over the last 3 years on average, earnings per share has increased by 4% per year but the company’s share price has increased by 28% per year, which means it is tracking significantly ahead of earnings growth. New Risk • Mar 19
New minor risk - Market cap size The company's market capitalization is less than US$100m. Market cap: HK$519.3m (US$66.3m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (22% average weekly change). Minor Risk Market cap is less than US$100m (HK$519.3m market cap, or US$66.3m). Announcement • Mar 13
Kaisa Health Group Holdings Limited to Report Fiscal Year 2025 Results on Mar 25, 2026 Kaisa Health Group Holdings Limited announced that they will report fiscal year 2025 results on Mar 25, 2026 Reported Earnings • Aug 31
First half 2025 earnings released: HK$0.002 loss per share (vs HK$0.005 loss in 1H 2024) First half 2025 results: HK$0.002 loss per share (improved from HK$0.005 loss in 1H 2024). Revenue: HK$69.6m (down 21% from 1H 2024). Net loss: HK$9.13m (loss narrowed 62% from 1H 2024). Over the last 3 years on average, earnings per share has increased by 53% per year but the company’s share price has fallen by 30% per year, which means it is significantly lagging earnings. Announcement • Aug 15
Kaisa Health Group Holdings Limited to Report First Half, 2025 Results on Aug 27, 2025 Kaisa Health Group Holdings Limited announced that they will report first half, 2025 results on Aug 27, 2025 New Risk • Jun 04
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Hong Kong stocks, typically moving 15% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (15% average weekly change). Market cap is less than US$10m (HK$65.5m market cap, or US$8.35m). New Risk • May 27
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: HK$75.6m (US$9.65m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Market cap is less than US$10m (HK$75.6m market cap, or US$9.65m). Minor Risk Share price has been volatile over the past 3 months (15% average weekly change). Reported Earnings • May 04
Full year 2024 earnings released: HK$0.009 loss per share (vs HK$0.001 profit in FY 2023) Full year 2024 results: HK$0.009 loss per share (down from HK$0.001 profit in FY 2023). Revenue: HK$185.4m (flat on FY 2023). Net loss: HK$46.4m (down HK$53.8m from profit in FY 2023). Over the last 3 years on average, earnings per share has increased by 34% per year but the company’s share price has fallen by 28% per year, which means it is significantly lagging earnings. Announcement • Apr 28
Kaisa Health Group Holdings Limited, Annual General Meeting, Jun 13, 2025 Kaisa Health Group Holdings Limited, Annual General Meeting, Jun 13, 2025, at 11:00 China Standard Time. Location: conference room a, office 1101-02, 11/f., euro trade centre, nos. 13-14 connaught road central, central, Hong Kong New Risk • Apr 07
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Hong Kong stocks, typically moving 14% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (14% average weekly change). Minor Risk Market cap is less than US$100m (HK$136.1m market cap, or US$17.5m). Reported Earnings • Mar 26
Full year 2024 earnings released: HK$0.009 loss per share (vs HK$0.001 profit in FY 2023) Full year 2024 results: HK$0.009 loss per share (down from HK$0.001 profit in FY 2023). Revenue: HK$185.4m (flat on FY 2023). Net loss: HK$46.4m (down HK$53.8m from profit in FY 2023). Over the last 3 years on average, earnings per share has increased by 34% per year but the company’s share price has fallen by 29% per year, which means it is significantly lagging earnings. Announcement • Mar 12
Kaisa Health Group Holdings Limited to Report Fiscal Year 2024 Results on Mar 24, 2025 Kaisa Health Group Holdings Limited announced that they will report fiscal year 2024 results on Mar 24, 2025 Announcement • Oct 22
Kaisa Health Group Holdings Limited Announces Appointment of Executive Directors The board of directors of Kaisa Health Group Holdings Limited announced that Mr. Liu Lihao ("Mr. Liu"), Ms. Luo Tingting ("Ms. Luo"), Mr. Xie Binhong ("Mr. Xie") and Mr. Yu Huiming ("Mr. Yu") have been appointed as executive directors of the Company with effect from 22 October 2024. The biographical details of Mr. Liu, Ms. Luo, Mr. Xie and Mr. Yu are set out below. Mr. LIU Lihao, aged 41, is an executive president and chief investment officer and an executive director of Kaisa Group Holdings Ltd. ("Kaisa Group"), the controlling shareholder of the Company, and is responsible for the management of investment and financing affairs of Kaisa Group. Mr. Liu joined Kaisa Group in August 2012 and served as the assistant president of its Real Estate Group (Beijing Region), the vice president of its Real Estate Group (Shanghai Region), the president and the chairman of its Shenzhen Group. Before joining Kaisa Group, Mr. Liu worked on commercial real estate analysis and operating management successively in DTZ Holdings Plc. and Guangming Technology Park Co. Ltd. of China Merchants Group. Mr. Liu has been a director of KAISA Jiayun Technology Inc. since 14 September 2022 and a director of Pacific Shuanglin Bio-pharmacy Co. Ltd. (a company listed on the main board of Shenzhen Stock Exchange, stock code 000403) since 21 May 2024. Mr. Liu graduated from Jiangxi University of Finance and Economics with bachelor's degrees of Economics and Laws. Ms. LUO Tingting, aged 39, is the chief financial officer and an executive director of Kaisa Group, and mainly responsible for financial management of Kaisa Group. Ms. Luo joined Kaisa Group in April 2011, and successively served as the general manager of the Planning and Finance Department of Kaisa Group and president assistant of Kaisa Group. She had worked in a major accounting firm before joining Kaisa Group. Ms. Luo graduated from Jiangxi University of Finance and Economics majoring in public finance and English with a double bachelor's degree of economics and arts in July 2006. Mr. Xie Binhong, aged 41, was appointed as the Chief Human Resources Officer of Kaisa Group in April 2020. Mr. Xie joined Kaisa Group in 2011 and has successively served as assistant to the president of its Commercial Group, vice president of its Shenzhen Region, vice president of its Real Estate Group, executive vice president of its International Group, and senior vice president of Kaisa Group. Mr. Xie was an executive director of Kaisa Prosperity Holdings Limited from August 2023 to April 2024. Before joining Kaisa Group, Mr. Xie had worked in Financial Street Huizhou Real Estate Co. Ltd. Mr. Xie graduated from Peking University in June 2018 with a master's degree in business administration. Mr. Yu Huiming aged 34, is the assistant president of the Company, and is mainly responsible for capital market, finance, human resource and legal work of the Group. Mr. Yu joined Kaisa Group in 2021, and successively served as the general manager of investment banking division, the head of the capital market division of Kaisa Group. He had worked in KPMG Huazhen LLP as an associate in financial service, Country Garden Holdings Company Limited as investment director, China Vanke Co. Ltd. as investment director before joining Kaisa Group. Mr. Yu graduated from Shanghai University of Finance and Economics with a bachelor's degree of Management and Columbia University in the City of New York with a master's degree of science. Reported Earnings • Oct 01
First half 2024 earnings released: HK$0.005 loss per share (vs HK$0.008 profit in 1H 2023) First half 2024 results: HK$0.005 loss per share (down from HK$0.008 profit in 1H 2023). Revenue: HK$88.5m (down 4.4% from 1H 2023). Net loss: HK$24.3m (down 161% from profit in 1H 2023). Over the last 3 years on average, earnings per share has remained flat but the company’s share price has fallen by 47% per year, which means it is significantly lagging earnings. New Risk • Sep 03
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: HK$75.6m (US$9.70m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Market cap is less than US$10m (HK$75.6m market cap, or US$9.70m). Minor Risk Share price has been volatile over the past 3 months (10% average weekly change). Announcement • Aug 15
Kaisa Health Group Holdings Limited to Report First Half, 2024 Results on Aug 27, 2024 Kaisa Health Group Holdings Limited announced that they will report first half, 2024 results on Aug 27, 2024 Announcement • May 28
Kaisa Health Group Holdings Limited Announces Board Retirements Kaisa Health Group Holdings Limited announced that it has been notified by Mr. Wu Tianyu ("Mr. Wu") and Mr. Zhang Huagang ("Mr. Zhang") that each of them wishes to devote more time to his personal endeavours, and will not offer himself for re-election at the AGM after retirement. As such, each of Mr. Wu and Mr. Zhang will retire from office as an executive Director with effect from the conclusion of the AGM. Following his retirement, Mr. Wu will also cease to be a member of the Remuneration Committee and a co-vice chairman of the board of director of the Company. As a result of Mr. Wu's retirement, Mr. Kwok Ying Shing, an executive Director, will be appointed as a member of the Remuneration Committee with effect from the conclusion of the AGM. Announcement • May 01
Kaisa Health Group Holdings Limited, Annual General Meeting, Jun 14, 2024 Kaisa Health Group Holdings Limited, Annual General Meeting, Jun 14, 2024, at 11:00 China Standard Time. Location: Conference Room A, Office 1101-1102, 11/F., Euro Trade Centre, Nos. 13-14 Connaught Road Central Central Hong Kong Agenda: To consider and approve the audited consolidated financial statements of the Company and its subsidiaries; to consider and approve the election of Directors; to consider and approve the appointment of additional directors; to consider and approve the re-appointment of the Elite Partners CPA Limited as auditor of the Company and to authorize the board of directors of the Company to fix their remuneration; and to consider and approve any other matters. Reported Earnings • Mar 27
Full year 2023 earnings released: EPS: HK$0.002 (vs HK$0.024 loss in FY 2022) Full year 2023 results: EPS: HK$0.002 (up from HK$0.024 loss in FY 2022). Revenue: HK$185.9m (down 2.9% from FY 2022). Net income: HK$7.47m (up HK$130.8m from FY 2022). Profit margin: 4.0% (up from net loss in FY 2022). Over the last 3 years on average, earnings per share has fallen by 9% per year but the company’s share price has fallen by 46% per year, which means it is performing significantly worse than earnings. Announcement • Mar 14
Kaisa Health Group Holdings Limited to Report Fiscal Year 2023 Results on Mar 25, 2024 Kaisa Health Group Holdings Limited announced that they will report fiscal year 2023 results on Mar 25, 2024 Reported Earnings • Sep 02
First half 2023 earnings released: EPS: HK$0.008 (vs HK$0.019 loss in 1H 2022) First half 2023 results: EPS: HK$0.008 (up from HK$0.019 loss in 1H 2022). Revenue: HK$92.6m (down 1.5% from 1H 2022). Net income: HK$40.0m (up HK$137.0m from 1H 2022). Profit margin: 43% (up from net loss in 1H 2022). Over the last 3 years on average, earnings per share has increased by 43% per year but the company’s share price has fallen by 41% per year, which means it is significantly lagging earnings. Announcement • Aug 24
Kaisa Health Group Holdings Limited Provides Group Earnings Guidance for the Six Months Ended 30 June 2023 Kaisa Health Group Holdings Limited provided group earnings guidance for the six months ended 30 June 2023. The board of directors of the company informed the shareholders of the company and potential investors that, based on a preliminary assessment on the unaudited consolidated management accounts of the Group for the six months ended 30 June 2023 and information currently available to the Board, the Group is expected to record a profit attributable to the owners of the Company of not less than HKD 35 million for the six months ended 30 June 2023 which will be improved as compared to the net loss attributable to the owners of the company in the amount of approximately HKD 97 million for the six months ended 30 June 2022. Announcement • Aug 18
Kaisa Health Group Holdings Limited to Report First Half, 2023 Results on Aug 28, 2023 Kaisa Health Group Holdings Limited announced that they will report first half, 2023 results on Aug 28, 2023 Announcement • May 13
Kaisa Health Group Holdings Limited, Annual General Meeting, Jun 21, 2023 Kaisa Health Group Holdings Limited, Annual General Meeting, Jun 21, 2023, at 10:00 China Standard Time. Location: Conference Centre, 10/F, United Centre, 95 Queensway Admiralty, Hong Kong Hong Kong China Agenda: To approve the audited consolidated financial statements of the Company and its subsidiaries and the reports of the directors and the independent auditor of the Company for the year ended 31 December 2022; to approve the re-election of Mr. Kwok Ying Shing as an executive director of the Company; to approve the re-election of Mr. Luo Jun as an executive director of the Company; and to consider other matters. Reported Earnings • Mar 30
Full year 2022 earnings released: HK$0.024 loss per share (vs HK$0 in FY 2021) Full year 2022 results: HK$0.024 loss per share (further deteriorated from HK$0 in FY 2021). Revenue: HK$191.5m (down 8.6% from FY 2021). Net loss: HK$123.3m (down HK$125.7m from profit in FY 2021). Over the last 3 years on average, earnings per share has increased by 58% per year but the company’s share price has fallen by 28% per year, which means it is significantly lagging earnings. Board Change • Nov 16
Less than half of directors are independent Following the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 4 non-independent directors. Independent Non-Executive Director Zhiying Li was the last independent director to join the board, commencing their role in 2021. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Announcement • Oct 11
Kaisa Health Group Holdings Limited Announces Board Changes The board of directors of Kaisa Health Group Holdings Limited announced that Mr. Zhang Huagang (Mr. Zhang) has resigned as the chairman of the Board and the chairman of the nomination committee of the company and remained as an executive Director with effect from 10 October 2022 in order to devote more time to other business engagements. Mr. Kwok Ying Shing (Mr. Kwok), an executive Director, has been appointed as the Chairman of the Board and the chairman of the Nomination Committee with effect from 10 October 2022. Mr. Kwok Ying Shing, aged 57, has been appointed as an executive Director, the Chairman of the Board and the chairman of the Nomination Committee with effect from 26 February 2019. Mr. Kwok resigned as the Chairman of the Board and the chairman of the Nomination Committee and remained as an executive Director from 9 April 2020. Mr. Kwok is the chairman, an executive director, the chairman of the nomination committee and a member of the remuneration committee and a substantial shareholder of Kaisa Group Holdings Ltd., a company listed on the Stock Exchange of Hong Kong Limited, and a controlling shareholder of the company. Mr. Kwok has extensive experience in real estate development, investment and financing management. Mr. Kwok is also the chairman and an executive director of Kaisa Capital Investment Holdings Limited, a company listed on the Stock Exchange, and the co-chairman and an executive director of Sing Tao News Corporation Limited. Reported Earnings • Oct 01
First half 2022 earnings released: HK$0.019 loss per share (vs HK$0.012 profit in 1H 2021) First half 2022 results: HK$0.019 loss per share (down from HK$0.012 profit in 1H 2021). Revenue: HK$94.0m (down 9.0% from 1H 2021). Net loss: HK$97.0m (down 260% from profit in 1H 2021). Over the last 3 years on average, earnings per share has increased by 51% per year but the company’s share price has fallen by 26% per year, which means it is significantly lagging earnings. Reported Earnings • Aug 31
First half 2022 earnings released: HK$0.019 loss per share (vs HK$0.012 profit in 1H 2021) First half 2022 results: HK$0.019 loss per share (down from HK$0.012 profit in 1H 2021). Revenue: HK$94.0m (down 9.0% from 1H 2021). Net loss: HK$97.0m (down 260% from profit in 1H 2021). Over the last 3 years on average, earnings per share has increased by 51% per year but the company’s share price has fallen by 22% per year, which means it is significantly lagging earnings. Announcement • Aug 23
Kaisa Health Group Holdings Limited Provides Unaudited Earnings Guidance for the Six Months Ended 30 June 2022 Kaisa Health Group Holdings Limited provided unaudited earnings guidance for the six months ended 30 June 2022. For the six months, the company it is expected the Group will record a loss attributable to the owners of the Company in the range of HKD 85 million to HKD 95 million as compared to the profit attributable to the owners of the Company in the amount of approximately HKD 61 million for the six months ended 30 June 2021. Announcement • Aug 18
Kaisa Health Group Holdings Limited to Report Q2, 2022 Results on Aug 29, 2022 Kaisa Health Group Holdings Limited announced that they will report Q2, 2022 results on Aug 29, 2022 Announcement • May 24
Kaisa Health Group Holdings Limited, Annual General Meeting, Jun 15, 2022 Kaisa Health Group Holdings Limited, Annual General Meeting, Jun 15, 2022, at 10:00 China Standard Time. Location: United Conference Centre, 10/F United Centre, 95 Queensway Admiralty Hong Kong Agenda: To consider, adopt and receive the audited consolidated financial statements of the Company and its subsidiaries (collectively, the "Group") and the reports of the directors and the independent auditor of the Company for the year ended 31 December 2021; to re-elect executives; to authorise the board of directors of the Company to appoint additional directors as and when the board considers necessary and appropriate; to authorise the board of directors of the Company to fix the respective directors' remuneration; to re-appoint Grant Thornton Hong Kong Limited as auditor of the Company and to authorise the board of directors of the Company to fix their remuneration; and to consider the other resolutions. Board Change • Apr 27
Less than half of directors are independent Following the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 4 non-independent directors. Independent Non-Executive Director Yonglan Li was the last independent director to join the board, commencing their role in 2021. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Reported Earnings • Apr 01
Full year 2021 earnings released: EPS: HK$0 (vs HK$0.008 loss in FY 2020) Full year 2021 results: EPS: HK$0 (up from HK$0.008 loss in FY 2020). Revenue: HK$209.6m (up 14% from FY 2020). Net income: HK$1.89m (up HK$41.6m from FY 2020). Profit margin: 0.9% (up from net loss in FY 2020). Over the last 3 years on average, earnings per share has increased by 32% per year but the company’s share price has fallen by 29% per year, which means it is significantly lagging earnings. Announcement • Mar 29
Kaisa Health Group Holdings Limited Provides Unaudited Consolidated Earnings Guidance for the Year Ended 31 December 2021 Kaisa Health Group Holdings Limited provided unaudited consolidated earnings guidance for the year ended 31 December 2021. The Group is expected to record a profit attributable to the owners of the Company in the range of HKD 1 million to HKD 3 million for the year ended 31 December 2021 as compared to the loss attributable to the owners of the Company in the amount of approximately HKD 40 million for the year ended 31 December 2020. Executive Departure • Dec 05
Executive Director Ho Lai Kwok has left the company On the 3rd of December, Ho Lai Kwok's tenure as Executive Director ended. We don't have any record of a personal shareholding under Ho Lai's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 2.25 years. Executive Departure • Dec 05
Co-President & Executive Director Hiu Yan Kwok has left the company On the 3rd of December, Hiu Yan Kwok's tenure as Co-President & Executive Director ended after less than a year in the role. We don't have any record of a personal shareholding under Hiu Yan's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 2.25 years. Reported Earnings • Oct 01
First half 2021 earnings released: EPS HK$0.012 (vs HK$0.001 loss in 1H 2020) The company reported a strong first half result with improved earnings, revenues and profit margins. First half 2021 results: Revenue: HK$103.3m (up 36% from 1H 2020). Net income: HK$60.7m (up HK$66.7m from 1H 2020). Profit margin: 59% (up from net loss in 1H 2020). Over the last 3 years on average, earnings per share has fallen by 22% per year but the company’s share price has only fallen by 7% per year, which means it has not declined as severely as earnings. Reported Earnings • Aug 30
First half 2021 earnings released: EPS HK$0.012 (vs HK$0.001 loss in 1H 2020) The company reported a strong first half result with improved earnings, revenues and profit margins. First half 2021 results: Revenue: HK$103.3m (up 36% from 1H 2020). Net income: HK$60.7m (up HK$66.7m from 1H 2020). Profit margin: 59% (up from net loss in 1H 2020). Over the last 3 years on average, earnings per share has fallen by 22% per year but the company’s share price has only fallen by 2% per year, which means it has not declined as severely as earnings. Announcement • May 25
An unknown buyer agreed to acquire Hangzhou Jiayue Investment Partnership/ Hangzhou Jinyun Investment Management Co., Ltd for approximately RMB 280 million. An unknown buyer agreed to acquire Hangzhou Jiayue Investment Partnership/ Hangzhou Jinyun Investment Management Co., Ltd for approximately RMB 280 million on May 24, 2021. As per the terms, the buyer will acquire 9.57% stake in Hangzhou Jiayue and 20% stake in Hangzhou Jinyun. Reported Earnings • Mar 25
Full year 2020 earnings released: HK$0.008 loss per share (vs HK$0.07 loss in FY 2019) The company reported a decent full year result with reduced losses and improved control over expenses, although revenues were weaker. Full year 2020 results: Revenue: HK$183.8m (down 27% from FY 2019). Net loss: HK$39.7m (loss narrowed 89% from FY 2019). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 60 percentage points per year, which is a significant difference in performance. Announcement • Mar 10
Kaisa Health Group Holdings Limited to Report Fiscal Year 2020 Results on Mar 24, 2021 Kaisa Health Group Holdings Limited announced that they will report fiscal year 2020 results on Mar 24, 2021 Executive Departure • Mar 10
Independent Non-Executive Director has left the company On the 4th of March, Hei Yu Fok's tenure as Independent Non-Executive Director ended after 3.0 years in the role. We don't have any record of a personal shareholding under Hei Yu's name. A total of 3 executives have left over the last 12 months. Announcement • Mar 10
Kaisa Health Group Holdings Limited Announces Executive Changes Kaisa Health Group Holdings Limited announced that Mr. Fok Hei Yu has tendered his resignation as an independent non-executive Director with effect from March 4, 2021 due to his personal needs to devote more time in other business commitments. Upon his resignation as an independent non- executive Director, Mr. Fok will also cease to be the chairman of the remuneration committee of the company and a member of the nomination committee of the company. Ms. Li Yonglan has been appointed as an independent non-executive Director and a member of the Audit Committee with effect from March 6, 2021; Dr. Lyu Aiping has been appointed as the chairman of the Remuneration Committee with effect from March 4, 2021; and Dr. Liu Yanwen has been appointed as a member of the Remuneration Committee and the Nomination Committee with effect from March 4, 2021. Announcement • Mar 04
Kaisa Health Group Holdings Limited and Shanghai Xinxing Construction Investment Co., Ltd Enter into Cooperation Agreement for the Establishment of the Project Company to Engage in the Project On 3 March 2021, Kaisa Health Group Holdings Limited and Shanghai Xinxing Construction Investment Co. Ltd. entered into the Cooperation Agreement in relation to, among other things, the establishment of the Project Company to engage in the Project. Upon establishment of the Project Company, the Project Company will be owned as to 80% by Shanghai Jiaxu (a wholly-owned subsidiary of the Company) and 20% by Fuhu Cooperative (the designated entity of Shanghai Xinxing) respectively. It is expected that the Project Company will be accounted for as a non-wholly owned subsidiary of the Company and its financial results will be consolidated into the consolidated financial statements of the Company. The total capital contribution committed by shareholders of the Project Company will be RMB 150 million, among which (i) RMB 120 million is committed by the Company by way of cash and (ii) RMB 30 million is committed by Shanghai Xinxing by way of set off against part of the Consideration payable for land use rights of the Collective Land. Reported Earnings • Sep 20
First half earnings released Over the last 12 months the company has reported total losses of HK$366.1m, with losses widening by HK$346.5m from the prior year. Total revenue was HK$209.0m over the last 12 months, down 11% from the prior year. Announcement • Aug 13
Kaisa Health Group Holdings Limited to Report First Half, 2020 Results on Aug 26, 2020 Kaisa Health Group Holdings Limited announced that they will report first half, 2020 results on Aug 26, 2020 